Skip to main content
Grant Details

Grant Number: 5R01CA163018-03 Interpret this number
Primary Investigator: Dorgan, Joanne
Organization: University Of Maryland Baltimore
Project Title: Prospective Study of Serum Mis and Gynecologic Cancer Risk
Fiscal Year: 2014


DESCRIPTION (provided by applicant): Several lines of evidence indicate a protective effect of Mullerian inhibiting substance (MIS) for ovarian and endometrial cancers. Objectives/Hypothesis: We hypothesize that premenopuasal women's circulating MIS concentrations are inversely associated with their risk of subsequently developing epithelial ovarian and endometrial cancer. Specific Aims: 1) Prospectively determine the association of premenopausal circulating MIS levels with risk of subsequent epithelial ovarian cancer; and 2) with risk of endometrial cancer. Study Design: A prospective case-control study will be conducted nested in 9 established cohorts including the Columbia, MO Serum Bank, CLUE I and CLUE II in Washington County Maryland, New York University (NYU) Women's Health Study, Nurses' Health Study, Guernsey, UK Cohort, Northern Sweden Health and Disease Study, European Prospective Investigation into Nutrition and Cancer (EPIC), Hormones and Diet in the Etiology of Breast Cancer (ORDET), and Shanghai Women's Health Study. The 9 cohorts include women who provided a blood sample at d 45 years old while premenopausal and subsequently developed invasive ovarian cancer (n=305) or endometrial cancer (n=373). For each of these cases, two controls will be selected matched on cohort, age and date of blood collection. MIS will be measured using a commercially available and validated MIS enzyme-linked immunosorbent assay (ELISA). Analysis will be conducted using conditional logistic regression. Significance: The proposed study will prospectively evaluate the association of a novel biomarker, MIS, with risk of developing ovarian and endometrial cancers. Results of the proposed study will increase our understanding of the etiologies of these cancers. The proposed study also could potentially identify new avenues for research on ovarian and endometrial cancer risk assessment and screening.


Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
Authors: Jung S. , Allen N. , Arslan A.A. , Baglietto L. , Barricarte A. , Brinton L.A. , Egleston B.L. , Falk R.T. , Fortner R.T. , Helzlsouer K.J. , et al. .
Source: International journal of cancer, 2018-01-15; 142(2), p. 262-270.
EPub date: 2017-10-04.
PMID: 28921520
Related Citations

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.
Authors: Fortner R.T. , Schock H. , Jung S. , Allen N.E. , Arslan A.A. , Brinton L.A. , Egleston B.L. , Falk R.T. , Gunter M.J. , Helzlsouer K.J. , et al. .
Source: British journal of cancer, 2017-10-24; 117(9), p. 1412-1418.
EPub date: 2017-09-05.
PMID: 28873086
Related Citations

Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.
Authors: Jung S. , Allen N. , Arslan A.A. , Baglietto L. , Brinton L.A. , Egleston B.L. , Falk R. , Fortner R.T. , Helzlsouer K.J. , Idahl A. , et al. .
Source: Fertility and sterility, 2017 Apr; 107(4), p. 1012-1022.e2.
PMID: 28366409
Related Citations

Back to Top